Targeting the enhancer of zeste homologue 2 in medulloblastoma

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1800-1809

  Alimova, Irina ^a   Venkataraman, Sujatha ^a   Harris, Peter ^a   Marquez, Victor E ^b   Northcott, Paul A ^c   Dubuc, Adrian ^c   Taylor, Michael D ^c   Foreman, Nicholas K ^a   Vibhakar, Rajeev ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Children's Hospital Colorado   (United States)

Author keywords

DZNEP; EZH2; histone lysine methylation; medulloblastoma; polycomb repressive complex 2

Indexed keywords

TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SOX2;

ADOLESCENT; ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN REGION; CANCER STEM CELL; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CEREBELLUM; CHILD; CHROMOSOME 7; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MEDULLOBLASTOMA; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN TARGETING; SCHOOL CHILD; TUMOR CELL; UPREGULATION;

ADENOSINE; ADOLESCENT; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CEREBELLAR NEOPLASMS; CEREBELLUM; CHILD; COLONY-FORMING UNITS ASSAY; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HISTONES; HUMANS; LUCIFERASES; MEDULLOBLASTOMA; NEOPLASTIC STEM CELLS; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84865339061     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27455     Document Type: Article

References (32)

1. Dhall G,. Medulloblastoma. J Child Neurol 2009; 24: 1418-30.
2. Packer RJ, Vezina G,. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 2008; 65: 1419-24.
3. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005; 23: 5511-19.
4. Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS, Termuhlen A, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer 2008; 50: 1169-75. (Pubitemid 351555540)
5. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-14.
6. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29: 1424-30.
7. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
8. Vibhakar R, Foltz G, Yoon JG, Field L, Lee H, Ryu GY, Pierson J, Davidson B, Madan A,. Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro Oncol 2007; 9: 135-44. (Pubitemid 46580315)
9. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, Ra YS, Zilberberg K, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009; 41: 465-72.
10. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-9.
11. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y,. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43. (Pubitemid 35247314)
12. Tsang DP, Cheng AS,. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
13. Margueron R, Reinberg D,. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-9.
14. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T,. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001; 21: 4330-6. (Pubitemid 32565314)
15. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA,. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-73. (Pubitemid 46622055)
16. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011; 10: 325-35.
17. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2011; 17: 443-54.
18. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL,. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 2011; 10: 40.
19. Crea F, Hurt EM, Farrar WL,. Clinical significance of Polycomb gene expression in brain tumors. Mol Cancer 2011; 9: 265.
20. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clement V, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-18.
21. Birks DK, Donson AM, Patel PR, Dunham C, Muscat A, Algar EM, Ashley DM, Kleinschmidt-Demasters BK, Vibhakar R, Handler MH, Foreman NK,. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol 2011; 13: 1296-307.
22. El-Sheikh A, Fan R, Birks D, Donson A, Foreman NK, Vibhakar R,. Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines. Pediatr Blood Cancer 2010; 55: 35-41.
23. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG,. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006; 66: 673-81. (Pubitemid 43165929)
24. Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009; 16: 533-46.
25. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q,. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050.
26. Parker MA, Anderson JK, Corliss DA, Abraria VE, Sidman RL, Park KI, Teng YD, Cotanche DA, Snyder EY,. Expression profile of an operationally-defined neural stem cell clone. Exp Neurol 2005; 194: 320-32. (Pubitemid 40966992)
27. Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G, Snyder E, Eberhart CG, Majumder S,. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol 2006; 26: 1666-78.
28. Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R,. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One 2010; 5: e10748.
29. Lund AH, van Lohuizen M,. Epigenetics and cancer. Genes Dev 2004; 18: 2315-35. (Pubitemid 39310518)
30. Albert M, Helin K,. Histone methyltransferases in cancer. Semin Cell Dev Biol 2011; 21: 209-20.
31. Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP,. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 2006; 66: 5582-91. (Pubitemid 43927108)
32. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11. (Pubitemid 37205983)